945530-36-9

Basic information

• Product Name: 2-((2-fluoro-4-iodophenyl)amino)thieno[2,3-b]pyridine-3-carboxylic acid
• Synonyms: 2-((2-fluoro-4-iodophenyl)amino)thieno[2,3-b]pyridine-3-carboxylic acid
• CAS NO: 945530-36-9
• Molecular Weight: 414.199
• Mol File: 945530-36-9.mol

Chemical Properties

• CAS DataBase Reference: 2-((2-fluoro-4-iodophenyl)amino)thieno[2,3-b]pyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((2-fluoro-4-iodophenyl)amino)thieno[2,3-b]pyridine-3-carboxylic acid(945530-36-9)
• EPA Substance Registry System: 2-((2-fluoro-4-iodophenyl)amino)thieno[2,3-b]pyridine-3-carboxylic acid(945530-36-9)

Safety Data

• Hazardous Substances Data: 945530-36-9(Hazardous Substances Data)

Upstream product

• 945530-35-8 2-methanesulfinylthieno[2,3-b]pyridine-3-carboxylic acid 
• 61494-55-1 2-Chloro-pyridin-3-yl acetic acid 
• 945530-32-5 2-fluoro-4-iodo-1-isothiocyanatobenzene 
• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 29632-74-4 2-fluro-4-iodoaniline 
• 166770-75-8 (2-chloropyridin-3-yl)methyl methanesulfonate 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 

Downstream Products

• 945530-37-0 (2R)-2-[({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridine-3-carbonyl}amino)methyl]pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1105071-03-1 2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridine-3-carboxylic acid [(trifluoromethyl)sulfonyl]amide 
• 1105070-58-3 N-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine 
• 1202067-21-7 3-[(2,2-dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrol-5-yl)carbonyl]-N-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine 
• 1202067-35-3 (cis-3,4-dihydroxypyrrolidin-1-yl)-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]methanone 
• 1202066-93-0 5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-3-methyl-hexahydropyrrolo[3,4-d]oxazol-2-one 
• 1202066-95-2 (3aR,6aS)-5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-tetrahydro[1,3]dioxolo[4,5-c]pyrrol-2-one 
• 1202067-94-4 [(3S,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202067-39-7 [(3R,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202067-89-7 [(3S,4R)-3-amino-4-hydroxypyrrolidin-1-yl]-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-methanone 
• 1202068-00-5 [2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-[(3S,4S)-3-hydroxy-4-(methylamino)pyrrolidin-1-yl]-methanone 
• 1202067-18-2 [2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridin-3-yl]-[(4aS,7aR)-hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl]-methanone 
• 1202067-23-9 5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione 
• 1202067-29-5 (3aS,6aR)-5-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-3-(methyl)hexahydropyrrolo[3,4-d]oxazol-2-one 

Relevant articles and documents

TOPICAL FORMULATIONS

Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS

Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, Rl3a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS

Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (1), (II), (III), (IV), and (V). wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS

A series of thieno[2,3-6]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fus

THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS

A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2- position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment, of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS

The invention provides a series of thieno[2,3-b]pyridine derivatives wherein Y represents a linkage of formula C(O) or S(O)2; R1 represents hydrogen, halogen, cyano, nitro, C|-6 alkyl, trifluoromethyl, Ci.6 alkoxy, trifluoromethoxy,